Cogent Biosciences Inc COGT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if COGT is a good fit for your portfolio.
News
-
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)
-
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
-
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
-
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
-
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
-
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
-
Cogent Biosciences stock drops as analysts see tough competition for mastocytosis treatment
Trading Information
- Previous Close Price
- $6.01
- Day Range
- $6.00–6.08
- 52-Week Range
- $3.67–13.44
- Bid/Ask
- $5.98 / $6.00
- Market Cap
- $574.16 Mil
- Volume/Avg
- 174,926 / 2.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 164
- Website
- https://www.cogentbio.com
Comparables
Valuation
|
Metric
|
COGT
|
VTYX
|
ANAB
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.62 | 1.03 | 5.82 |
Price/Sales | — | — | 30.24 |
Price/Cash Flow | — | — | — |
Price/Earnings
COGT
VTYX
ANAB
Financial Strength
|
Metric
|
COGT
|
VTYX
|
ANAB
|
|---|---|---|---|
Quick Ratio | 6.96 | 11.33 | 10.62 |
Current Ratio | 7.09 | 11.87 | 10.87 |
Interest Coverage | — | — | −9.09 |
Quick Ratio
COGT
VTYX
ANAB
Profitability
|
Metric
|
COGT
|
VTYX
|
ANAB
|
|---|---|---|---|
Return on Assets (Normalized) | −49.77% | −48.02% | −23.50% |
Return on Equity (Normalized) | −75.04% | −51.90% | −75.96% |
Return on Invested Capital (Normalized) | −59.65% | −55.64% | −68.56% |
Return on Assets
COGT
VTYX
ANAB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gymxyhmcd | Dhcrf | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Slyzzmd | Tsmxx | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bwzmztv | Bfxhcsb | $97.8 Bil | |
MRNA
| Moderna Inc | Hzzcqngjf | Dltbv | $38.8 Bil | |
ARGX
| argenx SE ADR | Skkxfcn | Cdkk | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Pplpgzm | Qqtm | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dbqvcwwvy | Zbgfbh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hqcxtdzx | Fctqsc | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vphwsbbkz | Dnkfq | $12.5 Bil | |
INCY
| Incyte Corp | Sxtsygtv | Dcwgnk | $11.5 Bil |